PSR-Agility Wins Second Consecutive ROAR Award for “Best Orphan Drug CRO”

The PSR-Agility Orphan Drug Development partnership has for the second consecutive year been awarded “Best Orphan Drug Contract Research Organisation” in the Rare & Orphan Advocacy and Research (ROAR) Awards.

The ROAR Awards were announced during the 5th Annual World Orphan Drug Congress Europe, 12–14 November 2014, in Brussels, Belgium. The 2014 awards recognize those who have done outstanding work in the rare disease field, honour those who have made significant contributions to the development of the sector, and celebrate the great achievements made in the world of orphan drugs in the last year.

“Successively winning this award as the PSR-Agility Orphan Drug Development partnership is a clear appreciation by all stakeholders of our continued commitment in the rare disease community,” says Roger Legtenberg, CEO of PSR Orphan Experts. “Our efforts to provide crucial patient assistance by a range of services to lower the burden of rare disease patients in clinical trials, together with added infrastructure to be able to offer innovative patient recruitment solutions, have among others contributed considerably towards winning this award.”

“We’re thrilled that our commitment to innovating clinical development strategies for clients developing orphan drugs has been recognized consistently during our company’s first 2 years of partnership,” says Ellen Morgan, CEO of Agility. “Our vision for making a difference by dedicating ourselves to this specialty has become a reality.”

Orphan drugs present fundamentally different regulatory and operational challenges compared to their traditional counterparts. PSR-Agility Orphan Drug Development specializes in assisting companies to develop efficiencies and economies of scale to bring innovative new orphan products to market, thereby contributing to the IRDiRC 2020 goal to deliver 200 new therapies for rare diseases. Our staff are all highly engaged to the rare disease cause, by providing education, taking part in fundraising events and being involved in public-private partnerships. Building successful partnerships with all stakeholders, including patient organizations, industry and key opinion leaders, and actively collaborating with them, is of crucial importance.